5AM Ventures, a firm led by Scott Rocklage, is one of several medical investment firms investing in helping Expansion Therapeutics find a cure for myotonic dystrophy type 1. DM 1, as the disorder is better known, is a genetic disorder caused by RNAs molecules accumulating to a toxic level within the body.

 

Expansion Therapeutics will use the money invested by Scott Rocklage’s firm to attempt to develop a treatment protocol or medications that might treat or prevent DM 1. Scott Rocklage has used his expertise to help Expansion Therapeutics bring together a top research team to find answers to the DM 1 disorder.

 

Matthew D. Disney will head up the research team. Scott Rocklage believes that Dr. Disney has the experience necessary to help find a cure for DM 1. Learn more: https://www.dialdish.com/scott-rocklage-seeks-to-conquer-cancer-by-targeting-mutant-rna-molecules/

 

Dr. Rocklage, and the team at Expansion Therapeutics, will also be working on small molecule medications that will be utilized to treat DM 1. With the combination of these two approaches, it is hoped that a cure for DM 1 will be forthcoming in the near future.

 

Scott Rocklage has spent over 30 years within the field of healthcare management. During his career, he has helped in the development of several drugs in the clinical trials phase. Three important drugs that Dr. Rocklage helped to developed are approved and on the market helping patients today.

 

Dr. Rocklage has served as the CEO of both Cubist Pharmaceuticals and NycomedSalutar. He is on the board of several pharmaceutical companies including Epirus and Pulmatrix. He is also managing partner of 5AM Ventures. This firm is helping companies achieve breakthroughs in the development of new drugs and new treatments for a variety of diseases and conditions.